Supernus Pharmaceuticals financials
$43.97−1.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $392.8M | $408.9M | $302.2M | $215.0M |
| Gross profit | $644.4M | $583.9M | $523.7M | $580.0M | $504.7M | $467.9M | $376.1M | $393.5M | $287.0M | $203.0M |
| Gross margin | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% | 95.8% | 96.2% | 95.0% | 94.4% |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $144.4M | $99.5M | $54.2M |
| Net income | -$38.5M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $111.0M | $57.3M | $91.2M |
| Net margin | −5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% |
| Diluted EPS | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 |
| EBITDA | $29.3M | $162.1M | $99.8M | $131.2M | $112.1M | $193.7M | $155.2M | $151.5M | $107.7M | $56.6M |
| Operating cash flow | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M | $136.5M | $143.1M | $129.0M | $114.6M | $66.8M |
| Free cash flow | $46.0M | $171.2M | $110.5M | $116.4M | $125.1M | $132.8M | $141.7M | $128.1M | $112.6M | $65.2M |
| Diluted shares | 56.5M | 56.0M | 55.5M | 61.7M | 54.4M | 53.7M | 53.8M | 54.1M | 53.3M | 51.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $128.4M | $69.3M | $75.1M | $93.1M | $203.4M | $288.6M |
| Short-term investments | $180.2M | $384.3M | $179.8M | $368.2M | $136.2M | $133.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $402.0M | $379.3M | $361.8M |
| Total assets | $1.45B | $1.37B | $1.28B | $1.70B | $1.69B | $1.50B |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M | $759.2M |
| Shareholders' equity | $1.06B | $1.04B | $921.5M | $886.2M | $815.9M | $744.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology